LifeMD, Inc. (NASDAQ:LFMD) Short Interest Up 37.3% in March

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 2,650,000 shares, a growth of 37.3% from the March 15th total of 1,930,000 shares. Based on an average daily trading volume, of 762,800 shares, the short-interest ratio is presently 3.5 days. Currently, 8.6% of the company's shares are sold short.

Hedge Funds Weigh In On LifeMD

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in LifeMD by 8.0% during the 4th quarter. Vanguard Group Inc. now owns 1,026,492 shares of the company's stock worth $8,510,000 after buying an additional 76,028 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of LifeMD in the fourth quarter worth about $137,000. Barclays PLC raised its position in shares of LifeMD by 116.8% during the fourth quarter. Barclays PLC now owns 49,373 shares of the company's stock worth $409,000 after purchasing an additional 26,604 shares during the period. Occudo Quantitative Strategies LP acquired a new position in LifeMD in the 4th quarter worth $543,000. Finally, G2 Investment Partners Management LLC increased its holdings in LifeMD by 23.9% during the 4th quarter. G2 Investment Partners Management LLC now owns 688,050 shares of the company's stock worth $5,704,000 after purchasing an additional 132,850 shares in the last quarter. 35.52% of the stock is owned by institutional investors.

LifeMD Trading Down 5.5 %

Shares of LifeMD stock traded down $0.56 during trading on Friday, reaching $9.66. 762,118 shares of the company were exchanged, compared to its average volume of 668,152. LifeMD has a twelve month low of $1.40 and a twelve month high of $12.01. The business has a 50-day moving average price of $8.57 and a 200-day moving average price of $7.47. The company has a quick ratio of 1.15, a current ratio of 1.22 and a debt-to-equity ratio of 3.22. The firm has a market capitalization of $389.97 million, a price-to-earnings ratio of -13.80 and a beta of 1.43.

LifeMD (NASDAQ:LFMD - Get Free Report) last announced its quarterly earnings results on Monday, March 11th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. The company had revenue of $44.86 million during the quarter, compared to the consensus estimate of $40.65 million. Sell-side analysts anticipate that LifeMD will post -0.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on LFMD. BTIG Research boosted their target price on LifeMD from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Friday, March 15th. HC Wainwright upped their target price on shares of LifeMD from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Thursday, January 11th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, LifeMD has an average rating of "Buy" and an average price target of $10.20.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.